Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
August 20 2019 - 4:05PM
Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that Andrew Cheng, M.D., Ph.D., has been appointed to the
Arbutus Board of Directors effective August 17, 2019.
“We are pleased to welcome Dr. Cheng to the
Arbutus Board,” said Dr. Frank Torti, Chairman of the Arbutus Board
of Directors. “I am confident Dr. Cheng, who brings a wealth of
clinical development expertise in antivirals to our Board, will be
of great value to our efforts to deliver a cure for people with
chronic HBV.”
Dr. Cheng is currently President and Chief
Executive Officer of Akero Therapeutics (Nasdaq: AKRO), a
biotechnology company focused on the development of
transformational treatments for non-alcoholic steatohepatitis
(NASH) and other serous metabolic diseases.
Previously, Dr. Cheng spent nearly two decades
at Gilead Sciences, Inc., where he most recently served as Chief
Medical Officer and Executive Vice President. Dr. Cheng joined
Gilead Sciences in 1999 and was responsible for leading the
clinical development for numerous HIV/AIDS programs. During his
tenure at Gilead, he also led the clinical development operations
for several other therapeutic areas including oncology,
inflammatory, respiratory and cardiovascular indications. Dr. Cheng
received a B.A. from the Johns Hopkins University and a M.D. and
Ph.D. from Columbia University College of Physicians and Surgeons.
He is board certified in Internal Medicine.
"I look forward to working with the Arbutus
Board of Directors and Executive Team as the Company looks to
advance its two lead compounds through Phase 1a/1b clinical
trials,” said Dr. Cheng. "I believe that Arbutus’ diverse pipeline,
focused solely on HBV, holds great promise for people suffering
from HBV.”
William Collier, President and Chief Executive
Officer of Arbutus, added, “Dr. Cheng has extensive experience in
the pharmaceutical industry and has achieved numerous successful
clinical development outcomes for several antiviral compounds. We
look forward to his guidance as we prepare for multiple clinical
readouts from our HBV pipeline in the 2019/2020 timeframe.”
About Arbutus
Arbutus Biopharma Corporation is a publicly
traded (Nasdaq: ABUS) biopharmaceutical company dedicated to
discovering, developing and commercializing a cure for patients
suffering from chronic Hepatitis B infection. Arbutus is developing
multiple drug candidates, each of which have the potential to
improve upon the standard of care and contribute to a curative
combination regimen. For more information, visit
www.arbutusbio.com.
Forward-Looking Statements and
Information
This press release contains forward-looking
statements within the meaning of the Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
and forward-looking information within the meaning of Canadian
securities laws (collectively, “forward-looking statements”).
Forward-looking statements in this press release include statements
about our ability to deliver a cure for people with chronic HBV and
our expectation for multiple clinical readouts from our HBV
pipeline in the 2019/2020 timeframe.
With respect to the forward-looking statements
contained in this press release, Arbutus has made numerous
assumptions regarding, among other things: the effectiveness and
timeliness of preclinical and clinical trials, and the usefulness
of the data; the timeliness of regulatory approvals; the continued
demand for Arbutus’ assets; and the stability of economic and
market conditions. While Arbutus considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause Arbutus' actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements contained herein. Known risk factors
include, among others: anticipated pre-clinical studies and
clinical trials may be more costly or take longer to complete than
anticipated, and may never be initiated or completed, or may not
generate results that warrant future development of the tested drug
candidate; Arbutus may not receive the necessary regulatory
approvals for the clinical development of Arbutus' products;
economic and market conditions may worsen; and market shifts may
require a change in strategic focus.
A more complete discussion of the risks and
uncertainties facing Arbutus appears in Arbutus' Annual Report on
Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus'
continuous and periodic disclosure filings, which are available at
www.sedar.com and at www.sec.gov. All forward-looking statements
herein are qualified in their entirety by this cautionary
statement, and Arbutus disclaims any obligation to revise or update
any such forward-looking statements or to publicly announce the
result of any revisions to any of the forward-looking statements
contained herein to reflect future results, events or developments,
except as required by law.
Contact Information
InvestorsWilliam H.
CollierPresident and CEOPhone: 604-419-3200Email:
ir@arbutusbio.com
MediaPam MurphyInvestor
Relations ConsultantPhone: 604-419-3200Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024